Harnessing Wolbachia-induced conditional infertility for control of the malaria mosquito
Project Number1K99AI185151-01
Contact PI/Project LeaderADAMS, KELSEY LEANNE
Awardee OrganizationHARVARD SCHOOL OF PUBLIC HEALTH
Description
Abstract Text
Project Summary:
Wolbachia endosymbionts hold strong potential for the control of vector-borne infections. Indeed, these bacteria
are currently used to control dengue virus transmission by Aedes aegypti, where they combine the ability to
spread through populations via Cytoplasmic Incompatibility (CI) with efficient blocking of arboviral infections. For
decades, however, scientists have been puzzled by the apparent lack of both natural and artificial Wolbachia
infections in Anopheles, the vectors of human malaria, with only a handful of examples reported. Wolbachia are
genetically intractable, making functional study of both their reproductive manipulations and this host tropism
difficult. However, my previous work suggests that a Wolbachia-derived CI-inducing factor, CifB, causes severe
abnormalities in females (rescued by a different gene, cifA), that may in part prevent Wolbachia from establishing
natural infections in Anopheles mosquitoes. I will elucidate the mechanisms regulating Wolbachia infections in
Anopheles, while gaining general mechanistic insight into CI in insects. Using a combination of genetics, cell
biology, molecular, genomic and bioinformatics approaches to address key questions related to Wolbachia
toxicity and rescue across different insects, these studies will push the field of insect-endosymbiont interactions
into new areas of inquiry and will also generate tools for the generation of Wolbachia-based strategies for the
control of malaria-transmitting Anopheles populations.
I will conduct the K99 phase of this award as a post-doctoral researcher in Dr. Flaminia Catteruccia’s group at
the Harvard T.H. Chan School of Public Health. The laboratory is exceptionally well-equipped to establish
transgenic insects and is one of the only vector biology labs with a robotic micro-injector and a COPAS Biosorter
in addition to a world-class Plasmodium infection facility. Dr. Catteruccia is supported by the Howard Hughes
Medical Institute, which allows flexibility of research funds which can be drawn upon for this project, and
facilitates access to state-of-the-art equipment, facilitating expansive research in vector biology. In addition to
Dr. Catteruccia’s expertise in mosquito reproduction, mosquito transgenesis, and host-parasite interactions, I will
be supported by Dr. Zhiyong Xi, an expert at the forefront of Wolbachia-based vector control implementation in
Aedes mosquitoes, and in establishing Wolbachia infections in Anopheles. Further, I will collaborate with Dr.
John Beckmann, a molecular biologist and biochemist with expertise working with Wolbachia’s CI-inducing
factors, and Dr. Lauren Childs, a mathematical modeling specialist. Additional mentors will include local
researchers Dr. Daniel Neafsey, who has vast experience with functional genomics in Wolbachia, Anopheles,
and Plasmodium, and Dr. Paul Garrity whose group excels at genetic engineering of various Dipterans. This
combination of expertise will train me to have a unique perspective and skillset to apply to research questions
related to tripartite interactions between Wolbachia, Anopheles and Plasmodium, with which I will be well-
positioned to establish an independent laboratory with a distinct set of research capabilities and questions.
Public Health Relevance Statement
Project Narrative: Associations between malaria-transmitting Anopheles mosquitoes and Wolbachia bacteria
are both rare in nature and challenging to establish in laboratory settings, precluding the utility of Wolbachia in
malaria control. It is not understood why Anopheles seem to be largely incompatible with Wolbachia infections,
despite these bacteria infecting an estimated 60% of insect species, including many other mosquitoes. In this
proposal, I outline a plan to investigate the basis of this incompatibility and overcome it, while simultaneously
pursuing an alternate use of Wolbachia-induced Cytoplasmic Incompatibility in a gene drive approach.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
149617367
UEI
UNVDZNFA8R29
Project Start Date
11-June-2024
Project End Date
31-May-2026
Budget Start Date
11-June-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$125,250
Direct Costs
$115,972
Indirect Costs
$9,278
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$125,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K99AI185151-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K99AI185151-01
Patents
No Patents information available for 1K99AI185151-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K99AI185151-01
Clinical Studies
No Clinical Studies information available for 1K99AI185151-01
News and More
Related News Releases
No news release information available for 1K99AI185151-01
History
No Historical information available for 1K99AI185151-01
Similar Projects
No Similar Projects information available for 1K99AI185151-01